Given the increase in health-related costs and limited health care resources, assessing the cost effectiveness of medical procedures is gaining considerable importance in the field of rheumatology; particularly, as the annual therapy costs of using TNF-blocking agents such as etanercept and infliximab (€17,000–21,000) are much higher than those of using DMARDs in the treatment of RA [24]. Here, TNF is linked to rheumatoid arthritis.